(Q37826018)

23 August 2017

1 reference

title

Anacetrapib and dalcetrapib: two novel cholesteryl ester transfer protein inhibitors (English)

1 reference

23 August 2017

Marta A Miyares

1

1 reference

23 August 2017

language of work or name

English

0 references

publication date

4 January 2011

1 reference

Annals of Pharmacotherapy

23 August 2017

published in

1 reference

23 August 2017

volume

45

1 reference

23 August 2017

issue

1

1 reference

23 August 2017

page(s)

84-94

1 reference

High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study

23 August 2017

cites work

1 reference

Racial differences in high-density lipoprotein cholesterol and coronary heart disease incidence in the usual-care group of the Multiple Risk Factor Intervention Trial

21 January 2018

1 reference

The Tromsø heart-study. High-density lipoprotein and coronary heart-disease: a prospective case-control study

21 January 2018

1 reference

High density lipoprotein cholesterol and incidence of coronary heart disease--the Israeli Ischemic Heart Disease Study

21 January 2018

1 reference

High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies

21 January 2018

1 reference

Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial

21 January 2018

1 reference

Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin

21 January 2018

1 reference

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

21 January 2018

1 reference

HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events

21 January 2018

1 reference

Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib

21 January 2018

1 reference

Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol

21 January 2018

1 reference

Effects of torcetrapib in patients at high risk for coronary events

21 January 2018

1 reference

The pharmacology and off-target effects of some cholesterol ester transfer protein inhibitors

21 January 2018

1 reference

Reverse cholesterol transport: high-density lipoprotein's magnificent mile

21 January 2018

1 reference

HDL: the metabolism, function, and therapeutic importance

21 January 2018

1 reference

Therapeutic elevation of HDL-cholesterol to prevent atherosclerosis and coronary heart disease

21 January 2018

1 reference

Inhibition of CETP as a novel therapeutic strategy for reducing the risk of atherosclerotic disease

21 January 2018

1 reference

Lipoprotein cholesteryl ester production, transfer, and output in vivo in humans

21 January 2018

1 reference

A review of CETP and its relation to atherosclerosis

21 January 2018

1 reference

Biochemical characterization of cholesteryl ester transfer protein inhibitors

21 January 2018

1 reference

Pharmacokinetics, metabolism, and excretion of anacetrapib, a novel inhibitor of the cholesteryl ester transfer protein, in rats and rhesus monkeys

21 January 2018

1 reference

Single-dose pharmacokinetics and pharmacodynamics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects

21 January 2018

1 reference

Multiple-dose pharmacodynamics and pharmacokinetics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects

21 January 2018

1 reference

Metabolism and excretion of anacetrapib, a novel inhibitor of the cholesteryl ester transfer protein, in humans.

21 January 2018

1 reference

Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies

21 January 2018

1 reference

Description of the torcetrapib series of cholesteryl ester transfer protein inhibitors, including mechanism of action

21 January 2018

1 reference

Assessment of the CYP3A-mediated drug interaction potential of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy volunteers

21 January 2018

1 reference

Assessment of a pharmacokinetic and pharmacodynamic interaction between simvastatin and anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects

21 January 2018

1 reference

Effect of JTT-705 on cholesteryl ester transfer protein and plasma lipid levels in normolipidemic animals

21 January 2018

1 reference

Consequences of cholesteryl ester transfer protein inhibition in patients with familial hypoalphalipoproteinemia

21 January 2018

1 reference

Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial

21 January 2018

1 reference

Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study

21 January 2018

1 reference

Coadministration of dalcetrapib with pravastatin, rosuvastatin, or simvastatin: no clinically relevant drug-drug interactions

21 January 2018

1 reference

A single-center, open-label, one-sequence study of dalcetrapib coadministered with ketoconazole, and an in vitro study of the S-methyl metabolite of dalcetrapib.

21 January 2018

1 reference

Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients

21 January 2018

1 reference

Safety of anacetrapib in patients with or at high risk for coronary heart disease

21 January 2018

1 reference

Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia

21 January 2018

1 reference

Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome.

21 January 2018

1 reference

Safety and tolerability of dalcetrapib

21 January 2018

1 reference

Lack of effect of dalcetrapib on QT interval in healthy subjects following multiple dosing

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.1P446

1 reference

23 August 2017

1 reference